CVR: 27394019
Secondary names: WELLCOME DANMARK A/S, WELLCOME BIOTECHNOLOGY A/S, WELLCOME DIAGNOSTICS A/S
Previous names: GLAXO LÆGEMIDLER A/S, GLAXO WELLCOME A/S, GLAXO DANMARK A/S
The financial health of GLAXOSMITHKLINE PHARMA A/S appears stable, with a consistent profit margin and a positive trajectory in revenue. In 2024, the company reported revenue of 548.47 million DKK and a profit of 12.24 million DKK, reflecting a growth trend from 474.48 million DKK in revenue and 12.00 million DKK in profit in 2023. Equity has also increased slightly to 38.13 million DKK, indicating a solid foundation for future growth. While the revenue growth is notable, the profit margins remain relatively stable, suggesting effective cost management. Positioned within the wholesale trade of pharmaceuticals and healthcare products, the company maintains a competitive stance in the industry.
AI-generated summary
Selskabets formål er at drive handel
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 548.5 mio. | 12.2 mio. | 99.1 mio. | 38.1 mio. | 73 | |
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Diederik Maarten Eijsvogel joined the board
Dominika M Wiktor-Brown left the board
Diederik Maarten Eijsvogel joined as director
Dominika M Wiktor-Brown left as director
Luciano Alves de Andrade joined the board
Patrick Gerard Connor left the board
Companies in the same industry and area
CVR 55541817
CVR 16406899
CVR 42541877
CVR 45267024
CVR 43401548
companydata.dk